Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VI 0134

Drug Profile

VI 0134

Latest Information Update: 18 Sep 2006

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator VIVUS
  • Class
  • Mechanism of Action Serotonin 3 receptor antagonists; Serotonin 4 receptor agonists; Serotonin 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Premature ejaculation

Most Recent Events

  • 18 Sep 2006 Discontinued - Phase-II for Premature ejaculation in USA (PO)
  • 15 May 2001 VIVUS has been granted a US patent for the use of serotonin-4 receptor agonists and antagonists in the treatment of premature ejaculation
  • 23 Mar 2000 VIVUS has been granted a US patent for the use of serotonin-3 receptor antagonists in the treatment of premature ejaculation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top